MichaelMaitlandMDPhD

Oncology • Fairfax, VA

Hematologic Oncology

Professor of Medicine, University of Virginia

Join to view full profile

Dr. Maitland is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Maitland's full profile

Already have an account?

Office
8081 Innovation Park Dr
Fairfax, VA 22031
Phone+1 571-472-4724

Fax+1 571-472-1601

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2003 - 2005
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2003
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2000 - 2002
Albert Einstein College of MedicineClass of 2000

Certifications & Licensure

VA State Medical License 2016 - 2026
IL State Medical License 2003 - 2017
NY State Medical License 2002 - 2004

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Sorafenib in Treating Patients With Advanced Solid Tumors Start of enrollment: 2007 Jan 01
Terminated
Phase 1
INNO-206 in Patients With Small Cell Lung Cancer (SCLC) Start of enrollment: 2008 May 01
Withdrawn
Phase 2
Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC Start of enrollment: 2010 Mar 01
Completed
Not Applicable
Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme Start of enrollment: 2009 Dec 01
Terminated
Phase 1
High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors Start of enrollment: 2011 Feb 09
Active, not recruiting
Phase 1
Phase 1 Study of OTS167 in Patients With Solid Tumors Start of enrollment: 2013 Aug 23
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Model-based approach to identify predictors of paclitaxel-induced myelosuppression in "real-world" administration.
Ahmed M Salem, Erik Dvergsten, Sanja Karovic, Michael L Maitland, Mathangi Gopalakrishnan
CPT. 2023-07-01
10 citations
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer WithAmplification, Overexpression, or Mutation: Results From the TAPUR Study.
Eugene R Ahn, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Hussein M Ali-Ahmad
JCO Precision Oncology. 2023-04-01
10 citations
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li
Clinical Cancer Research. 2023-03-14

Press Mentions

Public-Private Research Effort to Develop More Accurate Ways of Measuring Cancer ProgressionMarch 27th, 2017
Shop TalkSeptember 25th, 2016
Shop TalkSeptember 20th, 2016
Join now to see all